AvenCell raised $112 million in a Series B funding round led by Novo Holdings to accelerate clinical validation of its proprietary Universal Switchable CAR-T cell therapy platform.
Amount Raised
$112 Million
Round Type
Series B
CambridgeBiotechnologyHealth CareMedicalTherapeuticsInvestors
Description
AvenCell Therapeutics, Inc. has successfully raised $112 million in its Series B financing round. The funding, led by Novo Holdings and joined by new investors such as F-Prime Capital and Eight Roads Ventures Japan, will support the clinical development of its innovative CAR-T cell therapy platform.
Quick answer
AvenCell Therapeutics raised $112 Million in a Series B round, dated October 22, 2024. Investors: NYBC Ventures, F Prime Capital, Eight Roads Ventures Japan, Piper Heartland Healthcare Capital, Blackstone Life Sciences and Novo Holdings. AvenCell Therapeutics is based in Cambridge, Massachusetts, United States.
- How much did AvenCell Therapeutics raise?
- AvenCell Therapeutics raised $112 Million in a Series B round on October 22, 2024.
- Who invested in AvenCell Therapeutics?
- NYBC Ventures, F Prime Capital, Eight Roads Ventures Japan, Piper Heartland Healthcare Capital, Blackstone Life Sciences and Novo Holdings are named as investors in this round.
- What does AvenCell Therapeutics do?
- AvenCell Therapeutics, Inc. is a leading clinical-stage cell therapy company that focuses on advancing autologous and allogeneic switchable CAR-T cell therapies.
- Where is AvenCell Therapeutics based and how big is it?
- AvenCell Therapeutics is based in Cambridge, Massachusetts, United States. Fundz records about 63 employees.
- Who are the decision-makers at AvenCell Therapeutics?
- Fundz holds 2 contacts at AvenCell Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Medical and Therapeutics around the same time
Companies in the same sectors as AvenCell Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Orakl Oncology raised $12M (Seed) on December 3, 2024.
- TransCode Therapeutics raised $8M on December 2, 2024.
- Strata Oncology raised $6.1M on November 8, 2024.
- Blue Earth Therapeutics raised $77M (Series A) on October 31, 2024.
- Qnovia raised $14M on October 29, 2024.
- MAIA Biotechnology raised $2.4M (Seed) on October 28, 2024.
Who to call at AvenCell Therapeutics, and when
A new round usually means AvenCell Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day AvenCell Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at AvenCell Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at AvenCell Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment AvenCell Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAvenCell Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.